Dermatology drug developer raises $16M

Thesan Pharmaceuticals has been given $16 million in series A funding to develop novel treatments for inflammatory skin disorders.

Related Videos
Related Content

Fall Clinical Dermatology Conference for PAs and NPs Recap: Day 1

June 9th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Dermatology HCPs Previously Underestimated Patient Burden of Seborrheic Dermatitis

June 9th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Plan Your Trip: What to do While Visiting Orlando

June 9th 2023

Topical Skin Care Probiotics Made With New Technology Yield Numerous Benefits

June 9th 2023

Fall Clinical Dermatology Conference for PAs and NPs Recap: Day 1

June 9th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Dermatology HCPs Previously Underestimated Patient Burden of Seborrheic Dermatitis

June 9th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Plan Your Trip: What to do While Visiting Orlando

June 9th 2023

Topical Skin Care Probiotics Made With New Technology Yield Numerous Benefits

June 9th 2023

Fall Clinical Dermatology Conference for PAs and NPs Recap: Day 1

June 9th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Dermatology HCPs Previously Underestimated Patient Burden of Seborrheic Dermatitis

June 9th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Plan Your Trip: What to do While Visiting Orlando

June 9th 2023

Topical Skin Care Probiotics Made With New Technology Yield Numerous Benefits

June 9th 2023
© 2023 MJH Life Sciences

All rights reserved.